These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 36870990)
1. A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa. Saayman E; Hechter V; Kayuni N; Sonderup MW Harm Reduct J; 2023 Mar; 20(1):27. PubMed ID: 36870990 [TBL] [Abstract][Full Text] [Related]
2. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey. Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139 [TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh. Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689 [TBL] [Abstract][Full Text] [Related]
5. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB; Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989 [TBL] [Abstract][Full Text] [Related]
6. Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden. Lindqvist K; Thorin Z; Kåberg M Harm Reduct J; 2023 Jun; 20(1):72. PubMed ID: 37308951 [TBL] [Abstract][Full Text] [Related]
7. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. Litwin AH; Lum PJ; Taylor LE; Mehta SH; Tsui JI; Feinberg J; Kim AY; Norton BL; Heo M; Arnsten J; Meissner P; Karasz A; Mckee MD; Ward JW; Johnson N; Pericot-Valverde I; Agyemang L; Stein ES; Thomas A; Borsuk C; Blalock KL; Wilkinson S; Wagner K; Roche J; Murray-Krezan C; Anderson J; Jacobsohn V; Luetkemeyer AF; Falade-Nwulia O; Page K; Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1112-1127. PubMed ID: 36370741 [TBL] [Abstract][Full Text] [Related]
8. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387 [TBL] [Abstract][Full Text] [Related]
9. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia. Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E; Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159 [TBL] [Abstract][Full Text] [Related]
10. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol. Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686 [TBL] [Abstract][Full Text] [Related]
11. Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. Versfeld A; McBride A; Scheibe A; Spearman CW Harm Reduct J; 2020 Jun; 17(1):39. PubMed ID: 32522210 [TBL] [Abstract][Full Text] [Related]
12. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade. Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250 [TBL] [Abstract][Full Text] [Related]
13. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493 [TBL] [Abstract][Full Text] [Related]
14. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14). Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R; BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567 [TBL] [Abstract][Full Text] [Related]
15. Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis. Solomon SS; McFall AM; Lucas GM; Srikrishnan AK; Kumar MS; Anand S; Quinn TC; Celentano DD; Mehta SH PLoS Med; 2017 Nov; 14(11):e1002460. PubMed ID: 29182638 [TBL] [Abstract][Full Text] [Related]
16. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C). Rapoud D; Quillet C; Pham Minh K; Vu Hai V; Nguyen Thanh B; Nham Thi Tuyet T; Tran Thi H; Molès JP; Vallo R; Michel L; Feelemyer J; Weiss L; Lemoine M; Vickerman P; Fraser H; Duong Thi H; Khuat Thi Hai O; Des Jarlais D; Nagot N; Laureillard D; BMJ Open; 2020 Nov; 10(11):e039234. PubMed ID: 33208326 [TBL] [Abstract][Full Text] [Related]
17. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique. Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273 [TBL] [Abstract][Full Text] [Related]
18. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017). Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072 [TBL] [Abstract][Full Text] [Related]
19. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159 [TBL] [Abstract][Full Text] [Related]
20. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system. Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]